Medication Guide App

Nexavar Dosage

Generic name: sorafenib
Dosage form: tablet, film coated

This dosage information does not include all the information needed to use Nexavar safely and effectively. See full prescribing information for Nexavar.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

The recommended daily dose of NEXAVAR is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.

Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of NEXAVAR. When dose reduction is necessary, the NEXAVAR dose may be reduced to 400 mg once daily. If additional dose reduction is required, NEXAVAR may be reduced to a single 400 mg dose every other day [see Warnings and Precautions (5)].

Suggested dose modifications for skin toxicity are outlined in Table 1.

Table 1: Suggested Dose Modifications for Skin Toxicity

Skin Toxicity Grade

Occurrence

Suggested Dose Modification

Grade 1: Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema or discomfort of the hands or feet which does not disrupt the patient’s normal activities

Any occurrence

Continue treatment with NEXAVAR and consider topical therapy for symptomatic relief

Grade 2: Painful erythema and swelling of the hands or feet and/or discomfort affecting the patient’s normal activities

1st occurrence

Continue treatment with NEXAVAR and consider topical therapy for symptomatic relief

If no improvement within 7 days, see below

No improvement within 7 days or 2nd or 3rd occurrence

Interrupt NEXAVAR treatment until toxicity resolves to Grade 0–1

When resuming treatment, decrease NEXAVAR dose by one dose level (400 mg daily or 400 mg every other day)

4th occurrence

Discontinue NEXAVAR treatment

Grade 3: Moist desquamation, ulceration, blistering or severe pain of the hands or feet, or severe discomfort that causes the patient to be unable to work or perform activities of daily living

1st or 2nd occurrence

Interrupt NEXAVAR treatment until toxicity resolves to Grade 0–1

When resuming treatment, decrease NEXAVAR dose by one dose level (400 mg daily or 400 mg every other day)

3rd occurrence

Discontinue NEXAVAR treatment

 

No dose adjustment is required on the basis of patient age, gender, or body weight.

Concomitant strong CYP3A4 inducers: Avoid concomitant use of strong CYP3A4 inducers (such as, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. John’s wort), when possible, because inducers can decrease the systemic exposure to sorafenib [seeDrug Interactions (7.1)].

More about Nexavar (sorafenib)

Consumer resources

Professional resources

Compare with other treatments for:

Hide
(web2)